ORIC Pharmaceuticals
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by overcoming resistance in cancer. The company focuses on discovering and developing innovative therapies that address mechanisms of cancer treatment resistance, aiming to make existing therapies more effective and longer-lasting. Their pipeline includes several product candidates targeting various resistance mechanisms, with a strong leadership team and a mission to transform lives through advanced oncology treatments.
Industries
Nr. of Employees
medium (51-250)
ORIC Pharmaceuticals
Patents
Products
Clinical‑stage glucocorticoid receptor antagonist (lead program)
A potent, selective small‑molecule glucocorticoid receptor antagonist in clinical development for combination use to overcome resistance in solid tumors.
Orally bioavailable CD73 small‑molecule inhibitor (clinical‑stage)
An orally bioavailable small‑molecule inhibitor targeting CD73 to modulate the adenosine pathway implicated in resistance to chemotherapy and immunotherapy; in early clinical evaluation.
Allosteric PRC2 (EED) inhibitor (clinical‑stage for prostate cancer)
A selective, allosteric small‑molecule inhibitor of the PRC2 complex with demonstrated pharmacodynamic biomarker reduction (H3K27me3) in preclinical studies and in early clinical development.
Brain‑penetrant EGFR/HER2 exon‑20 inhibitor (in‑licensed program)
A brain‑penetrant, orally bioavailable inhibitor designed to target EGFR and HER2 exon 20 insertion mutations with preclinical evidence of intracranial activity; planned tumor‑agnostic clinical development.
Selective PLK4 inhibition discovery program
Discovery program to identify selective PLK4 inhibitors demonstrating synthetic lethality in TRIM37‑amplified cancer models, with assays correlating target engagement to cellular potency.
Clinical‑stage glucocorticoid receptor antagonist (lead program)
A potent, selective small‑molecule glucocorticoid receptor antagonist in clinical development for combination use to overcome resistance in solid tumors.
Orally bioavailable CD73 small‑molecule inhibitor (clinical‑stage)
An orally bioavailable small‑molecule inhibitor targeting CD73 to modulate the adenosine pathway implicated in resistance to chemotherapy and immunotherapy; in early clinical evaluation.
Allosteric PRC2 (EED) inhibitor (clinical‑stage for prostate cancer)
A selective, allosteric small‑molecule inhibitor of the PRC2 complex with demonstrated pharmacodynamic biomarker reduction (H3K27me3) in preclinical studies and in early clinical development.
Brain‑penetrant EGFR/HER2 exon‑20 inhibitor (in‑licensed program)
A brain‑penetrant, orally bioavailable inhibitor designed to target EGFR and HER2 exon 20 insertion mutations with preclinical evidence of intracranial activity; planned tumor‑agnostic clinical development.
Selective PLK4 inhibition discovery program
Discovery program to identify selective PLK4 inhibitors demonstrating synthetic lethality in TRIM37‑amplified cancer models, with assays correlating target engagement to cellular potency.
Expertise Areas
- Early‑stage oncology clinical development
- Biomarker development and translational science
- Medicinal chemistry and small‑molecule discovery
- DMPK and PK/PD translational support
Key Technologies
- Small‑molecule inhibitors (including irreversible and allosteric mechanisms)
- Brain‑penetrant kinase inhibitor design
- Allosteric epigenetic inhibition (PRC2 modulation)
- CD73 pathway modulation
News & Updates
South San Francisco, CA – March 9, 2015 – ORIC Pharmaceuticals, Inc., a privately-held company dedicated to the discovery and development of novel therapeutics for the treatment of cancer, announced today that Richard Scheller, Ph.D. will be joining its Board of Directors. Dr. Scheller spent 14 years leading research efforts that have yielded multiple FDA-approved drugs as chief scientific officer at Genentech and as executive vice president after its acquisition by the Roche Group.
South San Francisco, CA – March 9, 2015 – ORIC Pharmaceuticals, Inc., a privately-held company dedicated to the discovery and development of novel therapeutics for the treatment of cancer, announced today that Richard Scheller, Ph.D. will be joining its Board of Directors. Dr. Scheller spent 14 years leading research efforts that have yielded multiple FDA-approved drugs as chief scientific officer at Genentech and as executive vice president after its acquisition by the Roche Group.
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it has agreed to sell approximately 19.2 million shares of its common stock (or pre-funded warrants in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private placement, at a price per share of $6.50 (or $6.4999 per pre-funded warrant), representing a premium of approximately 18% to ORIC’s 10-day trailing volume-weighted average price as of deal signing on May 23, 2025.
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it has agreed to sell approximately 19.2 million shares of its common stock (or pre-funded warrants in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private placement, at a price per share of $6.50 (or $6.4999 per pre-funded warrant), representing a premium of approximately 18% to ORIC’s 10-day trailing volume-weighted average price as of deal signing on May 23, 2025.
ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing cancer treatments that address mechanisms of therapeutic resistance, announced the closing of a $55 million Series D financing. This financing brings the total capital raised by the Company to over $175 million. The round was led by new investors Arrowmark Partners and Invus Opportunities, who were joined by Hartford HealthCare Endowment, Casdin Capital, and others. Also participating were ORIC’s existing investors, including The Column Group, TopSpin Partners, OrbiMed, EcoR1 Capital, Fidelity Management & Research Company, City Hill Ventures, Memorial Sloan Kettering Cancer Center, Kravis Investment Partners, Foresite Capital, and Taiho Ventures.
ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing cancer treatments that address mechanisms of therapeutic resistance, announced the closing of a $55 million Series D financing. This financing brings the total capital raised by the Company to over $175 million. The round was led by new investors Arrowmark Partners and Invus Opportunities, who were joined by Hartford HealthCare Endowment, Casdin Capital, and others. Also participating were ORIC’s existing investors, including The Column Group, TopSpin Partners, OrbiMed, EcoR1 Capital, Fidelity Management & Research Company, City Hill Ventures, Memorial Sloan Kettering Cancer Center, Kravis Investment Partners, Foresite Capital, and Taiho Ventures.
South San Francisco, CA – March 9, 2015 – ORIC Pharmaceuticals, Inc., a privately-held company dedicated to the discovery and development of novel therapeutics for the treatment of cancer, announced today that Richard Scheller, Ph.D. will be joining its Board of Directors. Dr. Scheller spent 14 years leading research efforts that have yielded multiple FDA-approved drugs as chief scientific officer at Genentech and as executive vice president after its acquisition by the Roche Group.
South San Francisco, CA – March 9, 2015 – ORIC Pharmaceuticals, Inc., a privately-held company dedicated to the discovery and development of novel therapeutics for the treatment of cancer, announced today that Richard Scheller, Ph.D. will be joining its Board of Directors. Dr. Scheller spent 14 years leading research efforts that have yielded multiple FDA-approved drugs as chief scientific officer at Genentech and as executive vice president after its acquisition by the Roche Group.
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it has agreed to sell approximately 19.2 million shares of its common stock (or pre-funded warrants in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private placement, at a price per share of $6.50 (or $6.4999 per pre-funded warrant), representing a premium of approximately 18% to ORIC’s 10-day trailing volume-weighted average price as of deal signing on May 23, 2025.
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it has agreed to sell approximately 19.2 million shares of its common stock (or pre-funded warrants in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private placement, at a price per share of $6.50 (or $6.4999 per pre-funded warrant), representing a premium of approximately 18% to ORIC’s 10-day trailing volume-weighted average price as of deal signing on May 23, 2025.
ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing cancer treatments that address mechanisms of therapeutic resistance, announced the closing of a $55 million Series D financing. This financing brings the total capital raised by the Company to over $175 million. The round was led by new investors Arrowmark Partners and Invus Opportunities, who were joined by Hartford HealthCare Endowment, Casdin Capital, and others. Also participating were ORIC’s existing investors, including The Column Group, TopSpin Partners, OrbiMed, EcoR1 Capital, Fidelity Management & Research Company, City Hill Ventures, Memorial Sloan Kettering Cancer Center, Kravis Investment Partners, Foresite Capital, and Taiho Ventures.
ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing cancer treatments that address mechanisms of therapeutic resistance, announced the closing of a $55 million Series D financing. This financing brings the total capital raised by the Company to over $175 million. The round was led by new investors Arrowmark Partners and Invus Opportunities, who were joined by Hartford HealthCare Endowment, Casdin Capital, and others. Also participating were ORIC’s existing investors, including The Column Group, TopSpin Partners, OrbiMed, EcoR1 Capital, Fidelity Management & Research Company, City Hill Ventures, Memorial Sloan Kettering Cancer Center, Kravis Investment Partners, Foresite Capital, and Taiho Ventures.